BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 16153457)

  • 1. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma.
    Saad RS; El-Gohary Y; Memari E; Liu YL; Silverman JF
    Hum Pathol; 2005 Sep; 36(9):955-61. PubMed ID: 16153457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endoglin (CD105) expression in endometrial carcinoma.
    Saad RS; Jasnosz KM; Tung MY; Silverman JF
    Int J Gynecol Pathol; 2003 Jul; 22(3):248-53. PubMed ID: 12819391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma.
    El-Gohary YM; Silverman JF; Olson PR; Liu YL; Cohen JK; Miller R; Saad RS
    Am J Clin Pathol; 2007 Apr; 127(4):572-9. PubMed ID: 17369132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming growth factor-beta binding receptor endoglin (CD105) expression in esophageal cancer and in adjacent nontumorous esophagus as prognostic predictor of recurrence.
    Bellone G; Solerio D; Chiusa L; Brondino G; Carbone A; Prati A; Scirelli T; Camandona M; Palestro G; Dei Poli M
    Ann Surg Oncol; 2007 Nov; 14(11):3232-42. PubMed ID: 17682823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer.
    Saad RS; Liu YL; Nathan G; Celebrezze J; Medich D; Silverman JF
    Mod Pathol; 2004 Feb; 17(2):197-203. PubMed ID: 14657950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphatic vessel density as prognostic marker in esophageal adenocarcinoma.
    Saad RS; Lindner JL; Liu Y; Silverman JF
    Am J Clin Pathol; 2009 Jan; 131(1):92-8. PubMed ID: 19095571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma.
    Behrem S; Zarkovic K; Eskinja N; Jonjic N
    Croat Med J; 2005 Jun; 46(3):417-22. PubMed ID: 15861521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors.
    Basilio-de-Oliveira RP; Pannain VL
    World J Gastroenterol; 2015 Jun; 21(22):6924-30. PubMed ID: 26078569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD105 expression is an independent predictor of survival in patients with endometrial cancer.
    Erdem O; Taskiran C; Onan MA; Erdem M; Guner H; Ataoglu O
    Gynecol Oncol; 2006 Dec; 103(3):1007-11. PubMed ID: 16854456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
    Yacoub L; Goldman H; Odze RD
    Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
    Rubatt JM; Darcy KM; Hutson A; Bean SM; Havrilesky LJ; Grace LA; Berchuck A; Secord AA
    Gynecol Oncol; 2009 Mar; 112(3):469-74. PubMed ID: 19135712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endoglin (CD105) is a useful marker for evaluating microvessel density and predicting prognosis in esophageal squamous cell carcinoma.
    Sakurai T; Okumura H; Matsumoto M; Uchikado Y; Owaki T; Kita Y; Setoyama T; Omoto I; Kijima Y; Ishigami S; Natsugoe S
    Anticancer Res; 2014 Jul; 34(7):3431-8. PubMed ID: 24982351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
    Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
    Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The immunohistochemical expression of CD105 is a marker for high metastatic risk and worse prognosis in breast cancers].
    Charpin-Taranger C; Dales JP; Garcia S; Andrac-Meyer L; Ramuz O; Carpentier-Meunier S; Bonnier P
    Bull Acad Natl Med; 2003; 187(6):1129-45; discussion 1145-6. PubMed ID: 14978873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome.
    Dales JP; Garcia S; Andrac L; Carpentier S; Ramuz O; Lavaut MN; Allasia C; Bonnier P; Charpin C
    Int J Oncol; 2004 May; 24(5):1197-204. PubMed ID: 15067342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do angiogenesis and growth factor expression predict prognosis of esophageal cancer?
    Millikan KW; Mall JW; Myers JA; Hollinger EF; Doolas A; Saclarides TJ
    Am Surg; 2000 Apr; 66(4):401-5; discussion 405-6. PubMed ID: 10776879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microvessel Landscape Assessment in Pancreatic Ductal Adenocarcinoma: Unclear Value of Targeting Endoglin (CD105) as Prognostic Factor of Clinical Outcome.
    Lytras D; Leontara V; Kefala M; Foukas PG; Giannakou N; Pouliakis A; Dervenis C; Panayiotides IG; Karakitsos P
    Pancreas; 2015 Jan; 44(1):87-92. PubMed ID: 25058886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical expression of vascular endothelial growth factor (VEGF) does not correlate with microvessel density in renal cell carcinoma.
    Raica M; Cimpean AM; Anghel A
    Neoplasma; 2007; 54(4):278-84. PubMed ID: 17822316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGR5 expression in benign, preneoplastic and neoplastic lesions of Barrett's esophagus: Case series and findings.
    Marketkar S; Li D; Yang D; Cao W
    World J Gastroenterol; 2017 Feb; 23(8):1338-1344. PubMed ID: 28293080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphatic vessel density as a prognostic marker in clinical stage I endocervical adenocarcinoma.
    Saad RS; Ismiil N; Ghorab Z; Nofech-Mozes S; Dubé V; Covens A; Khalifa MA
    Int J Gynecol Pathol; 2010 Jul; 29(4):386-93. PubMed ID: 20567154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.